ArticleBritish journal of cancer2004
Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival.International journal of oncology · 2018Article
- Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.Journal of neuro-oncology · 2016Article
- Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions.BMC microbiology · 2016Article
- TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.Oncotarget · 2015Article
- Combination genetic signature stratifies lower-grade gliomas better than histological grade.Oncotarget · 2015Article
- TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Article
- Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review.Diagnostic pathology · 2014Review
- The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.Gene expression patterns : GEP · 2013Article
- Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction.Neoplasia (New York, N.Y.) · 2013Article
- Article
- Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.Molecular cancer research : MCR · 2012Article
- Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma.Chinese journal of cancer · 2011Article
- KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells.Brain pathology (Zurich, Switzerland) · 2010Article
- Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.Nature reviews. Cancer · 2010Review
- The quest for the 1p36 tumor suppressor.Cancer research · 2008Review
- 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas.Oncogene · 2008Article
- Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147.Molecular biology of the cell · 2007Article
- Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma.World journal of gastroenterology · 2006Article
- Attenuated expression of DFFB is a hallmark of oligodendrogliomas with 1p-allelic loss.Molecular cancer · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of the short arm of chromosome 1 is a hallmark of oligodendroglial tumours (OTs). Deletion mapping studies in OTs have revealed multiple commonly deleted regions on chromosome 1p, suggesting that there are more than one tumour suppressor gene. To map critical deletion regions on 1p, a series of 25 OTs were examined for loss of heterozygosity (LOH) on 19 polymorphic markers across the 1p arm using microsatellite analysis. Our study revealed that 60% of tumours had LOH of all informative markers on 1p and identified one tumour showing LOH at telomeric markers only. Since this deletion region lies in one of the critical deletion intervals defined previously, we then screened another series of 27 OTs specifically at 1p36.3 for LOH using nine polymorphic markers. A total of 12% (six out of 52) of tumours were found to carry interstitial deletions. The allelic status and the deletion breakpoints in these tumours with interstitial deletion were further verified by fluorescent in situ hybridisation. The small overlapping intervals facilitated the delineation of two contiguous minimally deleted regions of 0.76 Mb, defined by D1S468 and D1S2845, and of 0.41 Mb, bound by D1S2893 and D1S1608, on 1p36.31-36.32. Based on current reference human genome sequence these deletion regions have been sequenced almost to entirety and contain eight annotated genes. TP73, DFFB and SHREW1 are the only known genes located in these deletion regions, while the others are uncharacterised novel genes. In conclusion, our study has narrowed down the critical tumour suppressor loci on 1p36.3, in which two minimally deleted regions are mapped, and markedly reduced the number of candidate genes to be screened for their involvement in OT development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.